UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,412	03/25/2004	Kaoru Asano	11333/35	8939
Tadashi Horie	7590 08/24/200	7	EXAM	INER
Brinks Hofer Gilson & Lione			TOTH, KAREN E	
P.O. Box 1039: Chicago, IL 60			ART UNIT	PAPER NUMBER
ogo, -= 00			3735	
			<u></u>	
			MAIL DATE	DELIVERY MODE
			08/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

1) ☐ Responsive to communication(s) filed on 14 June 2007.  2a) ☐ This action is FINAL. 2b) ☐ This action is non-final.  3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) ☐ Claim(s) 1 and 3-38 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) ☐ Claim(s) is/are allowed.  6) ☐ Claim(s) 1, 3-20, 22, 24-29, 32, 34-36, 38 is/are rejected.  7) ☐ Claim(s) 21,23,30,31,33 and 37 is/are objected to.  8) ☐ Claim(s) are subject to restriction and/or election requirement.			•					
Examiner Karen E. Toth  3735  - The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Repty  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be a valiable under the provisions of 37 CPR 1.136(a), in no event, horework, may a reply be timely fixed.  If NO period for reply is specified above, the montrown attempt period val large and val segles 20, MONTHS from the malling date of this communication.  Fallium to reply white the set or extended period for reply vall, by disable, cause the application to become 48 ANDORED (93 U.S.C, § 133).  Arm gray process by the Office latent between semi-statutery period vall gape and ut segles 20, MONTHS from the malling date of this communication.  Fallium to reply white the set or extended period for reply vall, by disable, cause the application to become 48 ANDORED (93 U.S.C, § 133).  Arm gray process by the Office latent between semi-statutery period vall gape and ut segles 20, MONTHS from the malling date of the communication.  Page 2007.  This action is FINAL.  20) This action is non-final.  3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Exparte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1 and 3-38 is/are pending in the application.  4) Claim(s) 1 is/are allowed.  6) Claim(s) 1 is/are allowed.  6) Claim(s) 1 is/are allowed.  7) Claim(s) 1 is/are allowed.  8) Claim(s) 1 is/are allowed.  9) The specification is objected to by the Examiner.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Application papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.	1	Application No.	Applicant(s)					
Name   E. Toth   3735		10/810,412	ASANO ET AL.					
The MALING DATE of this communication appears on the cover sheet with the correspondence address—Period for Repty  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Extension of time may be a valiable under the provisions of 3 CFR 1.13(b), no event, however, may any be thinly filled indice 3X (b) MONTHS from the relating date of this communication of 3 CFR 1.13(b), no event, however, may a new by the timely filled indice 3X (b) MONTHS from the relating date of this communication. Fallute to represe the Mappellane ID of 15 CPR 1.15(d).  Fallute to represe the provision of th	Office Action Summary	Examiner	Art Unit					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Estrategies of lines may be available under the provisions of 37 GPR 1.36(a). In no event, however, may a way be timely filled.  Estrategies of lines nearly be available under the provisions of 37 GPR 1.36(a). In no event, however, may a way by be timely filled.  If NO provide or gray is specified above, the maximum statutory period value pays and vill expise 1xx (b) MONTHS from the mailing date of this communication.  Fabrico (reply visible the set of extended period for reply vill, by statute, cause the application to become ARANDOWED (35 U.S. 6, 133). Any raphy received by the Office less than these monities after the mailing date of this communication, even if linely filled, may reduce any eventual part of the mailing date of this communication, even if linely filled, may reduce any eventual part of the mailing date of this communication, even if linely filled, may reduce any eventual part of the mailing date of this communication, even if linely filled, may reduce any eventual part of the communication of the communication of the communication.  1) Responsive to communication(s) filled on 14 June 2007.  2a) This action is FINAL. 2b) This action is non-final.  3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1 and 3-38 is/are pending in the application.  4) Claim(s) 1 and 3-38 is/are pending in the application.  5 Claim(s) 1 and 3-38 is/are pending in the application.  6 Claim(s) 1 and 3-38 is/are allowed.  6 Claim(s) 1 and 3-38 is/are allowed.  7 Claim(s) 1 and 3-38 is/are allowed.  8 Claim(s) 1 and 3-38 is/are allowed.  8 Claim(s) 1 and 3-38 is/are allowed.  9 Claim(s) 1 and 3-38 is/are allowed.  9 Claim(s) 1 and 3-38 is/are allowed.  10 Claim(s) 1 and 3-38 is/are	· ·	Karen E. Toth	3735					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensives of time may be available under the provision of 3 CFR1-136(), in no event, flowers, may any by be limby filled  If NO period for reply is specified above, the maximum statiotry period will apply and will expire 31X (8) MONTHS from the mailing date of this communication. Fallute for reply will with the set or created be priod for inty will, by statics, cause the application become ABANDONE (34 U.S. C. § 137 CFR1-164(8)).  Status  1) Responsive to communication(s) filled on 14 June 2007.  2a) This action is FINAL.  2b) This action is non-final.  3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1.3-20. 22. 24-29. 32. 34-36. 38 is/are rejected.  7) Claim(s) 1.3-20. 22. 24-29. 32. 34-36. 38 is/are rejected.  7) Claim(s) 21.23.30.31.33 and 37 is/are objected to.  8) Claim(s) 21.23.30.31.33 and 37 is/are objected to.  8) Claim(s) 3.1-20. 22. 24-29. 32. 34-36. 38 is/are rejected.  7) Claim(s) 3.1-30. 31. 33 and 37 is/are objected to.  9) The specification is objected to by the Examiner.  Application Papers  9) The specification is objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * C) Mone of:  1. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attach		pears on the cover sheet	with the correspondence address					
WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Estations of time may be available under the provisions of 3 CFR 1.136(, in ne evert, however, may a reply be linely filed after SIX (6) MONTHS from the mailing date of this communication.  If NO period to reply in specified above, the maximum attentory period utility pays and vall reply and vall reply in the provision of this communication.  Any neply received by the Office better than three months after the mailing date of this communication, even if timely filed, may reduce any seamed patient term adjustment. See 37 CFR 1.704(b).  Status  1) □ Responsive to communication(s) filed on 14 June 2007.  2a) □ This action is FINAL.  2b) □ This action is non-final.  3) □ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) □ Claim(s) 1 and 3-38 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are allowed.  7) □ Claim(s) 21.23.30.31,33 and 37 is/are objected to.  8) □ Claim(s) are subject to restriction and/or election requirement.  Application Papers  9) □ The specification is objected to by the Examiner.  10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.  Application Papers  9) □ The specification is objected to by the Examiner.  10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.  Application Papers  9) □ The specification is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  11) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  11) □ Certified copies of the priority documents have been received in Application No  11 □ Certified copies of the prio	·	V IS SET TO EXPIRE 3	MONTH(S) OR THIRTY (30) DAYS					
1) ⊠ Responsive to communication(s) filed on 14 June 2007.  2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.  3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) ☒ Claim(s) 1 and 3-38 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) ☐ Claim(s) 1.3-20. 22. 24-29. 32. 34-36. 38 is/are rejected.  7) ☒ Claim(s) 21.23.30.31.33 and 37 is/are objected to.  8) ☐ Claim(s) = are subject to restriction and/or election requirement.  Application Papers  9) ☐ The specification is objected to by the Examiner.  10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	<ul> <li>WHICHEVER IS LONGER, FROM THE MAILING D</li> <li>Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.</li> <li>If NO period for reply is specified above, the maximum statutory period</li> <li>Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing</li> </ul>	DATE OF THIS COMMUN 136(a). In no event, however, may will apply and will expire SIX (6) Months, cause the application to become	APPLICATION.  a reply be timely filed  ONTHS from the mailing date of this communication.  ABANDONED (35 U.S.C. § 133).					
2a)  This action is FINAL. 2b)  This action is non-final.  3   Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4   Claim(s)  1 and 3-38 is/are pending in the application.  4a) Of the above claim(s)	Status		•					
2a)  This action is FINAL. 2b)  This action is non-final.  3   Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4   Claim(s)  1 and 3-38 is/are pending in the application.  4a) Of the above claim(s)	1) Responsive to communication(s) filed on 14 J	<u>lune 2007</u> .						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4)		<u> </u>						
Al) Claim(s) 1 and 3-38 is/are pending in the application. 4a) Of the above claim(s)	3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
4)	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed. 6) Claim(s) is/are allowed. 7) Claim(s) 21,23,30,31,33 and 37 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1 Certified copies of the priority documents have been received.  2 Certified copies of the priority documents have been received in Application No  3 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/58/08)	Disposition of Claims							
4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed. 6) Claim(s) is/are allowed. 7) Claim(s) 21,23,30,31,33 and 37 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1 Certified copies of the priority documents have been received.  2 Certified copies of the priority documents have been received in Application No  3 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/58/08)	4)⊠ Claim(s) 1 and 3-38 is/are pending in the appl	lication.						
6) Claim(s) 1, 3-20, 22, 24-29, 32, 34-36, 38 is/are rejected. 7) Claim(s) 21,23,30,31,33 and 37 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/58/08)	•							
Time (The proof of the priority documents have been received.  2. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)    Claim(s) 21.23.30.31.33 and 37 is/are objected to.   Claim(s) 21.23.30.31.33 and 37 is/are objected to.   Claim(s) 21.23.30.31.33 and 37 is/are objected to.   Priority and proof of the priority is/are objected to by the Examiner.   Objected to by the Examiner. Note the attached Office Action or form PTO-152.    Priority under 35 U.S.C. § 119   12	5) Claim(s) is/are allowed.		•					
Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	6) Claim(s) 1, 3-20, 22, 24-29, 32, 34-36, 38 is/a							
Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-992)  2) Notice of Toratsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	7) Claim(s) 21,23,30,31,33 and 37 is/are objected	ed to.						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  1) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	8) Claim(s) are subject to restriction and/o	or election requirement.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Oraflsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	Application Papers							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Oraflsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	9) The specification is objected to by the Examin	er.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	· — ·	•	o by the Examiner.					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2 Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)								
Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some col None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	11) The oath or declaration is objected to by the E	xaminer. Note the attach	ed Office Action or form PTO-152.					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	Priority under 35 U.S.C. § 119							
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application		n priority under 35 H.S.C	8 119(a)-(d) or (f)					
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)  1 Notice of Informal Patent Application		in priority under 55 5.5.5	. 3 110(a) (a) 51 (i).					
2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	· · · · · · · · · · · · · · · · · · ·							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)  1 Interview Summary (PTO-413) Paper No(s)/Mail Date.  5 Notice of Informal Patent Application								
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)  * See the attached detailed Office action for a list of the certified copies not received.  4) Interview Summary (PTO-413) Paper No(s)/Mail Date								
Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)  4) Interview Summary (PTO-413) Paper No(s)/Mail Date  5) Notice of Informal Patent Application								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application	* See the attached detailed Office action for a list of the certified copies not received.							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application			•					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application	Attachment(s)							
3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application	1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)							
3) Milliation disclosure statement(s) (1 10/00/00)	· · · · · · · · · · · · · · · · · · ·							
	, <del></del>							

### **DETAILED ACTION**

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Response to Arguments

2. Applicant's arguments filed 14 June 2007 have been fully considered but they are not persuasive.

Applicant has argued that Conn (US Patent 6438414) does not anticipate the claimed invention because it does not teach the claimed electrode contact areas with sufficient specificity – that is, Applicant feels that Conn's contact area range of 30 to 100 mm² does not anticipate the claimed range of .01 to 50 mm². Conn overlaps 40% of the claimed range; though Conn's preferred contact area is outside the claimed range, Conn clearly considers all values within the range to be appropriate for use. Applicant has stated that a contact area of less than 50 mm² provides unexpected results, but has not provided any evidence to support this allegation. As such, the Examiner feels that Conn does provide sufficient specificity to anticipate the present claims.

Regarding Applicant's argument that Conn does not disclose forming analyte transmission paths prior to application of the electrode, Conn also discloses techniques for enhancing transmission, such as pricking with microneedles, which would inherently form transmission paths before the electrodes are applied.

Art Unit: 3735

Regarding Applicant's argument that the range in Kim (US Patent 6736777) of 10 to 300 mm<sup>2</sup> does not have sufficient specificity to anticipate the claimed range of 0.01 to 50 mm<sup>2</sup>, Examiner must point out that Kim overlaps 80% of the claimed range. Again, though Kim's preferred area is greater than the claimed range, Applicant has not provided evidence of unexpected results that would render the overlapping range moot.

# Claim Rejections - 35 USC § 102

3. Claims 1, 4-7, 13, 15, 17-18, 24-25, 28-29, and 36 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Conn.

Regarding Claim 1, Conn discloses a device comprising a first electrode part (elements 4, 8 and 12) having a contact area of between about 0.01-50 mm<sup>2</sup> (column 18, lines 4-6); a second electrode part (element 14); and a component to supply power to the first and second electrodes in order to extract an analyte (column 15, lines 24-36).

Regarding Claim 4, Conn further discloses that the power supply part supplies a current of less than about 300 uA (column 15, lines 38-39).

Regarding Claim 5, Conn further discloses that the first electrode part comprises an electrode connected to the power source (element 14), and a collection material (elements 4 and 8) that is connected to the electrode (column 15, lines 29-36).

Regarding Claim 6, Conn further discloses that the collection material is in contact with the patient's skin (column 3, lines 54-59).

Art Unit: 3735

Regarding Claim 7, Conn further discloses that the electrode part is detachable from the power supply part (column 15, lines 24-25), since a non-rechargeable battery must be removed (detached) in order to allow replacement.

Regarding Claim 13, Conn further discloses that the power supply part may be a constant-voltage power supply (column 15, lines 24-25), because a battery supplies constant voltage.

Regarding Claim 15, Conn further discloses that the device may comprise a part for accelerating or promoting analyte extraction (column 8, line 64 - column 9, line 7).

Regarding Claim 17, Conn further discloses that the analyte is glucose (column 16, lines 39-43).

Regarding Claim 18, Conn further discloses that the overall system comprises an assay part for assaying the analyte extracted in the first electrode part and for outputting a signal corresponding to the analyte's concentration (column 16, lines 31-38); an analysis part for analyzing the concentration signal (column 18, lines 42-50); and an output part for outputting the analysis result (column 18, lines 47-48).

Regarding Claim 24, Conn discloses a method comprising placing two electrode parts on skin, one of which has a contact area of between about 0.01-50 mm<sup>2</sup> (column 15, lines 24-34; column 18, lines 4-6); applying electrical energy to the electrode parts (column 15, lines 27-34); and extracting analyte at the first electrode part (column 15, lines 34-36).

Regarding Claim 25, Conn further discloses that the contact area may be about 25 mm<sup>2</sup> (column 18, lines 4-6).

Art Unit: 3735

Regarding Claim 28, Conn further discloses that the method comprises outputting a signal corresponding to the analyte's concentration (column 16, lines 31-38); analyzing the concentration signal (column 18, lines 42-50); and outputting the analysis result (column 18, lines 47-48).

Regarding Claim 29. Conn discloses a method comprising forming analyte transmission paths in skin (column 8 line 60 to column 9 line 7); placing a throughcurrent electrode part and a first electrode part on skin in the location where the analyte transmission paths have already been formed, since the transmission enhancing techniques, such as pricking, would take place prior to application of electrodes (column 15, lines 24-34; column 18, lines 4-6); applying electrical energy to the electrode parts (column 15, lines 27-34); and extracting analyte at the first electrode part (column 15, lines 34-36).

Regarding claim 36, Conn further discloses that the first extraction electrode part may have a contact area with the skin of less than about 50 mm<sup>2</sup> (column 18, lines 4-6).

Claims 19, 20, and 22 are rejected under 35 U.S.C. 102(e) as anticipated by or, 4. in the alternative, under 35 U.S.C. 103(a) as obvious over Kim.

Regarding Claim 19, the examiner notes that the device of Kim is capable of being used as claimed because the device comprises a first electrode (element 40) with an area of less than 50 mm<sup>2</sup> (column 16, lines 65-67); an electrode for extracting an analyte (element 42); a through-current electrode (element 44); and a power supply used to supply power to all the electrodes (column 18, lines 11-20).

Art Unit: 3735

Regarding Claim 20, Kim further discloses that the contact area may be about 25 mm<sup>2</sup> (column 16, lines 65-67), because 0.3 cm<sup>2</sup> (30 mm<sup>2</sup>) is about 25 mm<sup>2</sup>.

Regarding Claim 22, Kim further discloses a second path-forming electrode (element 41) with an area of less than 50 mm<sup>2</sup> (column 16, lines 65-67); a second electrode for extracting an analyte (element 43); a second through-current electrode (element 45); and a power supply used to supply power to all the electrodes (column 18, lines 11-20).

5. Claims 3, 8-11, 26-27, and 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Conn in view of Avrahami (US Patent Application Publication 2004/0230227).

Regarding Claim 3, Conn discloses all the elements of the current application, as described above, except for the current flowing from the power supply part, through the through-current electrode into the skin, then into the first electrode part and finally back to the power supply part.

Avrahami discloses a transdermal analyte extraction device comprising a through-current electrode and a first electrode (elements 120 or 124) and a power supply (elements 50 and 98), wherein the current flows from the power supply part, through the through-current electrode into the skin, then into the first electrode part and finally back to the power supply part (Figure 4), in order to more efficiently extract analytes.

Art Unit: 3735

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn with the specific current flows of Avrahami, in order to more efficiently extract analytes.

Regarding Claim 8, Conn discloses all the elements of the current application, as described above, except for the device comprising a second electrode part having the same contact area as the first electrode part, and the power supply part of the device comprising power supplies for both the first and second electrode parts.

Avrahami discloses a transdermal analyte extraction device comprising a plurality of identical electrode parts (Figure 2), each with a power supply (Figure 4), in order to more thoroughly sample analytes from a patient.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn, with additional electrodes, each with a power supply, as taught by Avrahami, in order to more thoroughly sample analytes from a patient.

Regarding Claim 9, the plurality of duplicate electrode parts comprising the device of Conn in view of Avrahami may have a contact area of about 25 mm<sup>2</sup>, as taught by Conn (column 18, lines 4-6), because .3 cm<sup>2</sup> (30 mm<sup>2</sup>) is about 25 mm<sup>2</sup>.

Regarding Claim 10, the plurality of duplicate electrode parts comprising the device of Conn in view of Avrahami may each comprise an electrode (element 14) connected to the power part and an analyte collection material (elements 4 and 8) that contacts the electrode (column 15, lines 29-36).

Art Unit: 3735

Regarding Claim 11, Conn in view of Avrahami discloses all the elements of the current invention except for the first and second electrode parts being integrated.

Avrahami further discloses that the plurality of electrode parts are integrated within a single housing (Figure 2), in order to facilitate application upon a patient's skin.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn in view of Avrahami, and integrated the electrode parts, as taught by Avrahami, in order to facilitate application upon a patient's skin.

Regarding Claim 26, Conn discloses all the elements of the current invention, as described above, except for the method comprising placing a second electrode part having the same contact area as the first electrode part on the skin, supplying it with electrical energy, and extracting analyte at the duplicate electrode.

Avrahami discloses a method of transdermal analyte extraction comprising a placing a plurality of identical electrode parts (Figure 2) on a patient's skin, each with a power supply (Figure 4), and using them to transdermally extract analyte, in order to more thoroughly sample analytes from a patient.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the method of Conn, with the steps of adding, powering, and sampling from additional electrodes, as taught by Avrahami, in order to more thoroughly sample analytes from a patient.

Art Unit: 3735

Regarding Claim 27, Conn in view of Avrahami discloses all the elements of the current invention, as disclosed above, except for the first and second electrode parts being placed on the skin substantially simultaneously.

Avrahami further discloses that the plurality of electrode parts are disposed within a single housing (Figure 2) and are therefore placed on the skin substantially simultaneously, in order to more efficiently apply the sampling apparatus.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the method of Conn in view of Avrahami, and applied the electrode parts simultaneously, as taught by Avrahami, in order to more efficiently apply the sampling apparatus.

Regarding Claim 32, Conn discloses all the elements of the current invention, as described above, except for the method comprising placing a second extraction electrode part on the skin, supplying it with energy, and using it to extract analyte.

Avrahami discloses a method of transdermal analyte extraction comprising a placing a plurality of identical electrode parts (Figure 2) on a patient's skin, each with a power supply (Figure 4), and using them to transdermally extract analyte, in order to more thoroughly sample analytes from a patient.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the method of Conn, with the steps of adding, powering, and sampling from additional electrodes, as taught by Avrahami, in order to more thoroughly sample analytes from a patient.

Art Unit: 3735

Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Conn in 6. view of Glikfeld (US Patent 5279543).

Conn discloses all the elements of the current invention, as described above, except for the power supply part outputting a voltage of less than about 10 V.

Glikfeld teaches a device comprising a pair of electrodes for extraction of an analyte, where the power supplied by a power supply part is less than about 10 V (column 7, lines 63-64), in order to prevent harm to the patient from excess voltage.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn and used the power supply part to output a voltage of less than about 10 V, as taught by Glikfeld, in order to prevent harm to the patient from excess voltage.

Claims 12 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable 7. over Conn in view of Ackerman (US Patent Application Publication 2003/0208114).

Regarding Claim 12, Conn discloses all the elements of the current invention, as described above, except for the power supply part supplying constant current.

Ackerman discloses a device for transdermal analyte extraction comprising a part to supply direct (constant) current, in order to facilitate analyte extraction.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn, with a constant current power supply, as taught by Ackerman, in order to facilitate analyte extraction.

Art Unit: 3735

Regarding Claim 16, Conn discloses all the elements of the current invention, as described above, except for the extraction acceleration part comprising ultrasonic irradiation.

Ackerman discloses a device for transdermal analyte extraction comprising a part to apply ultrasonic irradiation, in order to facilitate analyte extraction.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have made the device of Conn with the part for applying ultrasonic irradiation, as taught by Ackerman, in order to facilitate analyte extraction.

## Allowable Subject Matter

- 8. Claims 21, 23, 30-31, 33 and 37 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 9. The following is a statement of reasons for the indication of allowable subject matter: The prior art of record fails to anticipate or make obvious the structure of claim 38, including, *inter-alia*, a transdermal analyte extraction device with an electrode with a skin-contacting area of about 0.01 to 25 mm<sup>2</sup>.

The allowability of these claims has been discussed in the previous office action.

#### Conclusion

Art Unit: 3735

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen E. Toth whose telephone number is 571-272-6824. The examiner can normally be reached on Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor, II can be reached on 571-272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Wet W

CHARLES A. MARMOR II
ERVISORY PATENT EXAMINE
CENTER 3700